RT info:eu-repo/semantics/article
T1 Presente y futuro del tratamiento anticoagulante oral
A1 García Frade, Luis Javier
A2 Ediciones Universidad de Valladolid
AB The alternative new oral anticoagulants open a new era in antithrombotic treatment. For more than half a century, vitamin K antagonists have defined oral anticoagulant therapy for the long-term management of thrombotic disorders. However, vitamin-K antagonists have multiple, well-known limitations, including numerous interactions with other drugs and the need for regular blood monitoring and dose adjustments. Novel anticoagulants are directed against either thrombin (Dabigatran) or factor Xa (Rivaroxaban and Apixaban), have a short half-life in patients with normal renal function and rapid onset of action. Thousands of patients in clinical trials in prophylaxis and treatment of venous and arterial thrombosis have been treated. Nowadays, they are approved for hip and knee replacement prophylaxis, non valvular atrial fibrillation, venous deep thrombosis and pulmonary embolism. Also, there are reports of their potential utility in recent coronary syndrome. Though open questions remains such as how to manage hemorrhage and invasive procedures and many aspects of their use will be unfamiliar to practicing clinicians, it seems that the paradigm of oral anticoagulation has completely changed. In the future, the question will probably be who should not receive a direct action oral anticoagulant
SN 0210-6523
YR 2014
FD 2014
LK http://uvadoc.uva.es/handle/10324/23861
UL http://uvadoc.uva.es/handle/10324/23861
LA spa
NO Anales de la Real Academia de Medicina y Cirugía de Valladolid, 2014, N.51, pags.113-128
DS UVaDOC
RD 24-nov-2024